In short
This article discusses the use of Bevacizumab Zirconium Zr-89 in clinical trials for patients with Neurofibromatosis Type 2 (NF2). The study aims to validate an imaging biomarker method to predict the effectiveness of bevacizumab treatment in NF2 patients. By using a specialized PET/CT scan with Zr-89 labeled bevacizumab, researchers hope to identify which patients are likely to respond positively to the treatment, potentially avoiding unnecessary side effects and costs for non-responders.
At a glance
- Study Type
- Observational clinical trial
- Condition
- Neurofibromatosis Type 2 (NF2)
- Intervention
- Bevacizumab Zirconium Zr-89 for imaging, followed by standard bevacizumab treatment
- Primary Objectives
- Validate imaging biomarker to predict bevacizumab efficacy
- Key Measurements
- Hearing response, radiographic response, vestibular function, quality of life
- Treatment Duration
- 6 months of bevacizumab therapy
- Follow-up Interval
- Every 3 months
What is Bevacizumab Zirconium Zr-89?
Bevacizumab Zirconium Zr-89 is an innovative imaging agent being studied for use in patients with Neurofibromatosis Type 2 (NF2). It is a modified version of a drug called bevacizumab (also known as Avastin), which is combined with a radioactive element called Zirconium-89. This combination allows doctors to use special imaging techniques to visualize tumors in NF2 patients.
The drug is also referred to as:
- 89Zr-Bevacizumab
- Avastin (when referring to the original bevacizumab drug)
Target Condition: Neurofibromatosis Type 2
Neurofibromatosis Type 2 (NF2) is a rare genetic disorder that causes tumors to grow on nerves in the brain and spinal cord. These tumors, while usually non-cancerous, can cause various symptoms including hearing loss, balance problems, and other neurological issues.
How Bevacizumab Zirconium Zr-89 Works
Bevacizumab Zirconium Zr-89 is used in combination with a special imaging technique called PET/CT (Positron Emission Tomography/Computed Tomography). Here's how it works:
- Patients receive a small dose (5 mg) of Bevacizumab Zirconium Zr-89 four days before the PET/CT scan.
- The drug travels through the bloodstream and attaches to the tumors.
- During the PET/CT scan, the Zirconium-89 emits signals that can be detected by the scanner, creating detailed images of where the drug has accumulated in the body.
- These images help doctors see the tumors and predict how well a patient might respond to treatment with regular bevacizumab.
Clinical Trial Overview
A clinical trial (NCT05685836) is currently studying Bevacizumab Zirconium Zr-89 in NF2 patients. The main goals of this trial are:
- To use Bevacizumab Zirconium Zr-89 PET/CT imaging to predict which patients will respond best to bevacizumab treatment.
- To monitor how well bevacizumab treatment works for NF2 patients over time.
In this trial, patients undergo a Bevacizumab Zirconium Zr-89 PET/CT scan before starting regular bevacizumab treatment. They then receive standard bevacizumab therapy (7.5 mg/kg) every three weeks for six months.
Potential Benefits
The use of Bevacizumab Zirconium Zr-89 imaging could potentially offer several benefits:
- Help predict which patients will respond best to bevacizumab treatment
- Avoid unnecessary treatment and potential side effects in patients who are unlikely to benefit
- Reduce financial burden by identifying non-responders early
- Improve overall treatment outcomes for NF2 patients
Outcome Measures
The clinical trial is measuring several outcomes to assess the effectiveness of the treatment:
- Hearing response: This is measured using tests like Word Recognition Score (WRS) and Pure Tone Average (PTA). These tests help determine if there's any improvement in hearing.
- Radiographic response: This involves measuring changes in tumor size and characteristics using MRI scans.
- Vestibular function: Tests like the Video-Head Impulse Test (vHIT) and cervical Vestibular Evoked Myogenic Potential (cVEMP) test are used to assess balance and inner ear function.
- Quality of life: Patients complete questionnaires about their symptoms and overall quality of life.
- Physical examination: Doctors perform neurological exams to check for any changes in symptoms or nerve function.
Safety Considerations
While the clinical trial is primarily focused on the effectiveness of Bevacizumab Zirconium Zr-89 as an imaging agent, it's important to note that the safety of patients is also being monitored. This includes:
- Regular check-ups during the treatment period
- Monitoring of kidney function through tests like creatinine clearance and estimated glomerular filtration rate (eGFR)
- Watching for potential side effects of bevacizumab treatment
It's crucial to remember that Bevacizumab Zirconium Zr-89 is still being studied, and more research is needed to fully understand its benefits and potential risks. Patients should always discuss their treatment options with their healthcare providers.